Gene rearrangement of bcl-1 and bcl-2 is confined to distinct subgroups of high-grade malignant B-cell lymphomas

1993 ◽  
Vol 169 (3) ◽  
pp. 303-307 ◽  
Author(s):  
M. Michaela Ott ◽  
Kathrin Dahlheimer ◽  
Hans K. Müller-Hermelink ◽  
Alfred C. Feller
2010 ◽  
Vol 23 (7) ◽  
pp. 909-920 ◽  
Author(s):  
Adam C Seegmiller ◽  
Rolando Garcia ◽  
Rong Huang ◽  
Atousa Maleki ◽  
Nitin J Karandikar ◽  
...  

2018 ◽  
pp. 613-617
Author(s):  
Faramarz Naeim ◽  
P. Nagesh Rao ◽  
Sophie X. Song ◽  
Ryan T. Phan
Keyword(s):  
B Cell ◽  

1999 ◽  
Vol 123 (12) ◽  
pp. 1208-1218 ◽  
Author(s):  
Margarita Topalovski ◽  
Domnita Crisan ◽  
Joan C. Mattson

Abstract Background.—Primary lymphomas of the breast are rare, accounting for 1.7% to 2.2% of extranodal lymphomas and 0.38% to 0.7% of all non-Hodgkin lymphomas. Although secondary breast lymphomas are also rare, they represent the largest group of metastatic tumors of the breast. Objectives.—To investigate the clinicopathologic and immunophenotypic characteristics of breast lymphomas, the relative frequency of primary and secondary mammary lymphomas, and in selected cases, the role of gene rearrangement analysis in diagnosis and staging of these lymphomas. Results.—We conducted a retrospective review of 22 cases of breast lymphoma diagnosed at William Beaumont Hospital, Royal Oak, Mich, during a 30-year period (1963–1994). Eleven of the 22 cases fulfilled the criteria for primary breast lymphoma; these cases represented 0.6% of all non-Hodgkin lymphomas seen in our hospital. Of the 11 cases, 5 were diffuse large B-cell lymphomas, 2 were follicle center lymphomas, 2 were marginal zone B-cell lymphomas (mucosa-associated lymphoid tissue type), 1 was a lymphoplasmacytoid lymphoma, and 1 was a peripheral B-cell neoplasm, unclassified. Using a panel of immunohistochemical stains (CD45RO, CD45RA, CD43, CD3, CD20, CD30, CD68, and HLA-DR), 8 cases demonstrated unequivocal B-cell phenotype and 3 cases had equivocal or weak staining patterns for B-cell markers. We identified no cases of T-cell lymphoma. Of 7 cases that had bone marrow biopsies for staging, 3 were positive morphologically for bone marrow involvement. Molecular analysis of B- and T-cell gene rearrangement was used to exclude bone marrow involvement in one case with bone marrow lymphoid aggregates and to confirm negativity in a case that was morphologically negative. Of the 11 secondary breast lymphomas, 5 were diffuse large B-cell lymphomas; 1 was diffuse large B-cell, primary mediastinal subtype; and 5 were follicle center lymphomas. Conclusions.—Breast lymphomas represented 1.2% of all non-Hodgkin lymphomas in this study; the frequency of primary and secondary cases was equal. In both groups, right breast lesions were predominant, and the most frequent morphologic type was diffuse large B-cell lymphoma. Gene rearrangement analysis is helpful in selected cases to rule out bone marrow involvement, especially in older patients, in whom lymphoid aggregates are common.


Pathology ◽  
2014 ◽  
Vol 46 (3) ◽  
pp. 211-215 ◽  
Author(s):  
Kyaw Lynnhtun ◽  
Jasveen Renthawa ◽  
Winny Varikatt

2017 ◽  
Vol 17 ◽  
pp. S51-S53
Author(s):  
Shaoying Li ◽  
Pei Lin ◽  
Carlos Bueso-Ramos ◽  
L. Jeffrey Medeiros
Keyword(s):  
B Cell ◽  

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S96-S97
Author(s):  
H Iqbal ◽  
A Harrington ◽  
S H Kroft

Abstract Introduction/Objective B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (double- and triple-hit lymphomas, DHL/THL) are a distinct entity due to shared biology and aggressive behavior, exhibiting poor outcomes with standard therapies. While pathologic features of DHL/THLs in primary sites have been well described, little information is available regarding the clinicopathologic features of bone marrow involvement by this entity. Methods/Case Report Files were searched from 2010-2020 for all DHL/THLs. Since mid-2016, all aggressive B-cell lymphomas were reflexed to DHL/THL FISH testing. Prior to that, criteria for performing FISH varied. Clinical and laboratory data were obtained through chart review. Both BM and primary diagnostic specimens were reviewed when possible. Results (if a Case Study enter NA) There were 46 DHL/THL cases with initial staging BM evaluations, of which 13 (28%) were positive for DHL/THL; 11 were available for review (5F:6M; 28-95 years). All patients with positive BMs were stage 3 or 4 irrespective of the BM findings. Lymphoma cytology in positive BMs was blastoid in 6, large cell in 2, and high grade, NOS in 3. The cytology in primary tissues was not significantly associated with the rate of marrow involvement. PB smears were available for 9/11 BM(+) cases; of these, 6 (66.7%) had circulating lymphoma cells in the blood, ranging from rare to greater than 40% lymphoma cells (median, 4%). Lymphoma cells with cytoplasmic vacuoles were present in 5 cases (45%). No BM infiltrates had a starry-sky appearance. Infiltration patterns included diffuse (3), diffuse and interstitial (3), and interstitial (3). One exhibited only rare, scattered lymphoma cells in the aspirate and core biopsy, and another with large cell morphology showed random focal (nodular) and focally paratrabecular infiltration. The proliferation index in the marrow infiltrates ranged from 50% to >90% (median, 65%). Flow cytometry was positive in 9 of 10 cases; the single negative study was from an outside institution Conclusion Our study demonstrates 28% of DHL/THLs show BM involvement at diagnosis. Notably, the peripheral blood was involved in 2/3 of cases with marrow infiltration (13% of total cases), ranging from rare circulating cells to frank leukemic involvement. Cytologically, the marrow infiltrates were predominantly blastoid or high grade NOS. Marrow infiltrates generally displayed leukemic rather than lymphomatous patterns of involvement.


2019 ◽  
Vol 1246 ◽  
pp. 012026
Author(s):  
Muslina ◽  
Nursanti Apriyani ◽  
Zen Hafy ◽  
Krisna Murti

Sign in / Sign up

Export Citation Format

Share Document